109 related articles for article (PubMed ID: 16322205)
1. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides.
Snyder EL; Saenz CC; Denicourt C; Meade BR; Cui XS; Kaplan IM; Dowdy SF
Cancer Res; 2005 Dec; 65(23):10646-50. PubMed ID: 16322205
[TBL] [Abstract][Full Text] [Related]
2. Cationic TAT peptide transduction domain enters cells by macropinocytosis.
Kaplan IM; Wadia JS; Dowdy SF
J Control Release; 2005 Jan; 102(1):247-53. PubMed ID: 15653149
[TBL] [Abstract][Full Text] [Related]
3. Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells.
Egorova A; Kiselev A; Hakli M; Ruponen M; Baranov V; Urtti A
J Gene Med; 2009 Sep; 11(9):772-81. PubMed ID: 19562713
[TBL] [Abstract][Full Text] [Related]
4. A peptide carrier for the delivery of biologically active proteins into mammalian cells.
Morris MC; Depollier J; Mery J; Heitz F; Divita G
Nat Biotechnol; 2001 Dec; 19(12):1173-6. PubMed ID: 11731788
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
6. TAT-RasGAP317-326 requires p53 and PUMA to sensitize tumor cells to genotoxins.
Michod D; Widmann C
Mol Cancer Res; 2007 May; 5(5):497-507. PubMed ID: 17510315
[TBL] [Abstract][Full Text] [Related]
7. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
8. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.
Ho A; Schwarze SR; Mermelstein SJ; Waksman G; Dowdy SF
Cancer Res; 2001 Jan; 61(2):474-7. PubMed ID: 11212234
[TBL] [Abstract][Full Text] [Related]
9. The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains.
Yoshikawa T; Sugita T; Mukai Y; Abe Y; Nakagawa S; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Jul; 30(19):3318-23. PubMed ID: 19304319
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of penetration domain and killing domain peptides.
Jarajapu YP; Baltunis J; Knot HJ; Sullivan SM
J Gene Med; 2005 Jul; 7(7):908-17. PubMed ID: 15832372
[TBL] [Abstract][Full Text] [Related]
11. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells.
Schabath H; Runz S; Joumaa S; Altevogt P
J Cell Sci; 2006 Jan; 119(Pt 2):314-25. PubMed ID: 16390867
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo.
Mi Z; Mai J; Lu X; Robbins PD
Mol Ther; 2000 Oct; 2(4):339-47. PubMed ID: 11020349
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
14. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains.
Tkachenko AG; Xie H; Liu Y; Coleman D; Ryan J; Glomm WR; Shipton MK; Franzen S; Feldheim DL
Bioconjug Chem; 2004; 15(3):482-90. PubMed ID: 15149175
[TBL] [Abstract][Full Text] [Related]
15. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models.
Yoon Y; Liang Z; Zhang X; Choe M; Zhu A; Cho HT; Shin DM; Goodman MM; Chen ZG; Shim H
Cancer Res; 2007 Aug; 67(15):7518-24. PubMed ID: 17671223
[TBL] [Abstract][Full Text] [Related]
16. CXC chemokine receptor CXCR4 expression enhances tumorigenesis and angiogenesis of basal cell carcinoma.
Chen GS; Yu HS; Lan CC; Chow KC; Lin TY; Kok LF; Lu MP; Liu CH; Wu MT
Br J Dermatol; 2006 May; 154(5):910-8. PubMed ID: 16634895
[TBL] [Abstract][Full Text] [Related]
17. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
[TBL] [Abstract][Full Text] [Related]
18. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide.
Sugita T; Yoshikawa T; Mukai Y; Yamanada N; Imai S; Nagano K; Yoshida Y; Shibata H; Yoshioka Y; Nakagawa S; Kamada H; Tsunoda S; Tsutsumi Y
Biochem Biophys Res Commun; 2007 Nov; 363(4):1027-32. PubMed ID: 17923117
[TBL] [Abstract][Full Text] [Related]
19. HIV-1-Tat potentiates CXCL12/stromal cell-derived factor 1-induced downregulation of membrane CXCR4 in T lymphocytes through protein kinase C zeta.
Hidalgo-Estévez AM; Punzón C; Sanchez-Duffhues G; Muñoz E; Fresno M
Mol Immunol; 2008 Nov; 46(1):106-15. PubMed ID: 18760839
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability.
Chu H; Zhou H; Liu Y; Liu X; Hu Y; Zhang J
Int J Biochem Cell Biol; 2007; 39(1):197-205. PubMed ID: 16973405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
